Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Boston Scientific Corp., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Net income (loss) 314 140 188 260 110 95 419 186 341 210 (155) (148) 11
(Gain) loss on disposal of businesses and assets 22 (30) (40) (2) (6)
Depreciation and amortization 285 294 284 284 274 290 272 263 268 289 282 275 277
Deferred and prepaid income taxes 19 7 23 (18) (75) (75) 39 (87) (1) (69) (28) 8 7
Stock-based compensation expense 55 55 58 55 52 49 51 47 47 42 40 46 42
Goodwill and other intangible asset impairment charges 125 7 197 128 45 81 219 49 184
Net (gain) loss on investments and notes receivable 31 (45) 10 16 20 (42) (186) 15 (37) (369) (63) 12 22
Contingent consideration net expense (benefit) 12 (33) 20 36 12 (19) (26) (85) (6) 2 6 (108)
Inventory step-up amortization 7 8 17 19 7 8 16 12 12 18
Debt extinguishment costs 194
Other, net (3) 33 59 12 20 29 12 13 23 187 10 (3) 50
Trade accounts receivable (86) (44) (14) (96) (66) (148) 14 (28) (117) 93 (123) 204 161
Inventories (185) (46) (95) (72) (108) (31) (215) 15 (115) (64) 35 163 (199)
Other assets (41) 89 (54) (104) (140) 11 55 (72) (128) (81) 60 (51) (128)
Accounts payable, accrued expenses and other liabilities (211) 335 (141) (81) (368) 133 (65) 333 7 336 348 (298) (414)
Increase (decrease) in operating assets and liabilities, excluding purchase accounting (523) 334 (304) (353) (682) (35) (211) 248 (353) 284 320 18 (580)
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities (124) 667 282 47 (168) 383 46 457 (57) 463 798 417 (88)
Cash provided by (used for) operating activities (legacy) 692 502 292 350 19 501 (403) 193
Cash provided by (used for) operating activities 190 807 470 307 (58) 478 465 643 284 673 643 269 (77) 692 502 292 350 19 501 (403) 193
Purchases of property, plant and equipment and internal use software (111) (212) (150) (105) (121) (266) (107) (106) (75) (159) (49) (68) (100) (186) (121) (91) (63) (106) (76) (74) (60)
Proceeds from sale of property, plant and equipment 3 2 1 1 8 4 3 3 4 6 2 1 3 2 3 2 14
Payments for acquisitions of businesses, net of cash acquired (375) (1) (72) 1 (1,470) (244) (1,309) (706) (1) (2) (1) (3,618) (442) (321) (480) (550) (409) (9)
(Payments for) proceeds from investments and acquisitions of certain technologies (10) 12 (22) 1 (15) 187 67 25 (15) (102) (27) (2) (11) (22) (87) (28) (23) (36) (8) (104)
Proceeds from disposal of certain businesses and assets 5 25 801 15 90
Proceeds from royalty rights 9 16 18 17 19 20 19 21 22 21 21 22 23 52
(Payments for) proceeds from settlements of hedge contracts 56 15 95 (294)
Cash (used for) provided by investing activities (484) (183) (225) (29) (1,574) (461) (1,207) 71 (147) (129) (59) (76) (49) (3,962) (620) (410) (595) (662) (491) (173)
Payment of contingent consideration previously established in purchase accounting (34) (1) (51) (264) (20) (1) (3) (11) (14) 3 (15) (23) (71) (57) (7) (3) (11) (5)
Payments for royalty rights (34) (36) (39) (43) (42) (45) (52)
Proceeds from royalty rights transfer 256
Payments on short-term borrowings (250) (250) (2,400) (300) (1,000)
Proceeds from short-term borrowings, net of debt issuance costs 1,245 1,000 700 999
Net increase (decrease) in commercial paper (155) (69) 223 (714) (588) (662) 305 370 424 (875) 788 (316)
Payments on borrowings from credit facilities (1,440) (479) (569)
Proceeds from borrowings on credit facilities 77 1,839 499 70
Payments on long-term borrowings and debt extinguishment costs (3,184) (260) (1,000) (2,088) (1,472) (602)
Proceeds from long-term borrowings, net of debt issuance costs (1) 3,271 1,683 986 2,000 4,243 (2) (1) 990
Cash dividends paid on preferred stock (14) (13) (14) (14) (14) (13) (14) (14) (14) (14) (14)
Net proceeds from issuance of preferred stock in connection with public offering 975
Net proceeds from issuance of common stock in connection with public offering 975
Payments for repurchase of common stock (535)
Cash used to net share settle employee equity awards (50) (4) (2) (1) (46) (2) (1) (1) (46) (2) (57) (1) (3) (1) (60) (2) (2) (2) (50)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans 63 19 59 5 53 8 64 20 18 4 59 5 42 11 50 9 53 8 40 16 38
Cash provided by (used for) financing activities (69) 1 (199) (344) (6) (8) 6 2 (95) (819) (249) 1,105 256 (724) 1,314 256 2,127 425 151 726 130
Effect of foreign exchange rates on cash 4 (7) (5) (1) (3) (2) 6 1 1 (10) 12 (2) (4) (6) 1
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents (363) 629 39 (71) (1,639) 9 (739) 645 258 (287) 266 1,316 93 (69) (2,148) (72) 2,067 (151) (14) (174) 151

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Cash flow statement item Description The company
Cash provided by (used for) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Boston Scientific Corp. cash provided by (used for) operating activities increased from Q3 2022 to Q4 2022 but then decreased significantly from Q4 2022 to Q1 2023.
Cash (used for) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Boston Scientific Corp. cash (used for) provided by investing activities increased from Q3 2022 to Q4 2022 but then decreased significantly from Q4 2022 to Q1 2023.
Cash provided by (used for) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Boston Scientific Corp. cash provided by (used for) financing activities increased from Q3 2022 to Q4 2022 but then slightly decreased from Q4 2022 to Q1 2023.